- Home
- FENC vs GNLX Comparison
FENC vs GNLX Comparison
Compare FENC & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- GNLX
- Stock Information
- Founded
- FENC 1996
- GNLX 2001
- Country
- FENC United States
- GNLX United States
- Employees
- FENC N/A
- GNLX N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- GNLX Health Care
- Exchange
- FENC Nasdaq
- GNLX Nasdaq
- Market Cap
- FENC 156.9M
- GNLX 184.4M
- IPO Year
- FENC 2001
- GNLX 2023
- Fundamental
- Price
- FENC $5.53
- GNLX $2.60
- Analyst Decision
- FENC Strong Buy
- GNLX Strong Buy
- Analyst Count
- FENC 2
- GNLX 4
- Target Price
- FENC $14.00
- GNLX $18.25
- AVG Volume (30 Days)
- FENC 126.0K
- GNLX 161.3K
- Earning Date
- FENC 05-13-2025
- GNLX 03-28-2025
- Dividend Yield
- FENC N/A
- GNLX N/A
- EPS Growth
- FENC N/A
- GNLX N/A
- EPS
- FENC N/A
- GNLX N/A
- Revenue
- FENC $47,538,000.00
- GNLX $8,000.00
- Revenue This Year
- FENC $2.68
- GNLX N/A
- Revenue Next Year
- FENC $71.63
- GNLX N/A
- P/E Ratio
- FENC N/A
- GNLX N/A
- Revenue Growth
- FENC 123.69
- GNLX N/A
- 52 Week Low
- FENC $3.96
- GNLX $1.60
- 52 Week High
- FENC $11.29
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- FENC 30.64
- GNLX 30.97
- Support Level
- FENC $6.25
- GNLX $3.03
- Resistance Level
- FENC $6.90
- GNLX $3.35
- Average True Range (ATR)
- FENC 0.36
- GNLX 0.37
- MACD
- FENC -0.09
- GNLX -0.12
- Stochastic Oscillator
- FENC 4.20
- GNLX 4.92
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.